Drug Trial Radar · NCT06624670
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Feb 5, 2025
Primary completion
Nov 12, 2027
Study completion Aug 19, 2028
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Boehringer Ingelheim
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm\^2 to 80 cm\^2 in size. This study has 2 parts. In Part 1, participants are put into groups randomly, which means by chance. 1 group gets spesolimab and the other group gets placebo. Placebo infusions look like spesolimab infusions, but do not contain any medicine. Every participant has a 2 in 3 chance of getting spesolimab. For the first 8 weeks, participants also take corticosteroid medicine by mouth. In Part 2, participants are put into groups again. Participants without open ulcers have an equal chance of getting spesolimab or placebo. Participants with open skin ulcers will get spesolimab. In both parts, participants receive spesolimab or placebo as an infusion into a vein every 4 weeks. Participants are in the study for about 1.5 years. During this time, they visit the study site 20 times. At study visits, doctors check the participant's skin for signs of PG. The doctors also regularly check participants' health and take note of any unwanted effects. The results of the groups are compared to see whether the treatment works.
Conditions
- Pyoderma Gangrenosum
Interventions
SpesolimabDrug
Solution for infusion
Placebo matching to spesolimabDrug
Placebo matching to spesolimab
PrednisoneDrug
Prednisone
PrednisoloneDrug
Prednisolone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of complete closure (PGAR-100 (100% pyoderma gangrenosum area reduction)) of the target PG ulcer at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later)Time frame: Up to Week 28.
Locations
104 sites in 21 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Medical Dermatology Specialists Phoenix
Phoenix, Arizona · Recruiting
University of California Irvine
Irvine, California · Recruiting
University of Miami
Miami, Florida · Recruiting
University of South Florida
Tampa, Florida · Recruiting
Advanced Medical Research PC
Sandy Springs, Georgia · Recruiting
Ada West Research
Meridian, Idaho · Recruiting
DeNova Research
Chicago, Illinois · Not yet recruiting
Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995
Indianapolis, Indiana · Recruiting
Tulane University Hospital and Clinic
New Orleans, Louisiana · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Dermatology & Cosmetic Center PLLC - Flint
Flint, Michigan · Recruiting
University Health Kansas
Kansas City, Missouri · Not yet recruiting
Red River Research Partners - Lee's Summit
Lee's Summit, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
Dartmouth Hitchcock Clinics Heater Road
Lebanon, New Hampshire · Recruiting
Dermatology at Lake Success
Lake Success, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Red River Research Partners, LLC
Fargo, North Dakota · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Oregon Health and Sciences University
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Epiphany Dermatology
Lewisville, Texas · Recruiting
University of Utah Health MidValley Dermatology
Murray, Utah · Recruiting
CIPREC
CABA, Argentina · Completed
Hospital Italiano de Buenos Aires
CABA, Argentina · Completed
Instituto de Especialidades de la Salud Rosario
Rosario, Argentina · Completed
Skin and Cancer Foundation
Darlinghurst, New South Wales, Australia · Recruiting
Royal North Shore Hospital-St Leonards-20807
St Leonards, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Not yet recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Medical University of Graz
Graz, Austria · Recruiting
LKH Salzburg University Hospital
Salzburg, Austria · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Chronos Pesquisa Clinica
Brasília, Brazil · Recruiting
Faculdade de Medicina do ABC
Santo André, Brazil · Recruiting
Centre de Recherche Saint-Louis
Québec, Canada · Recruiting
Rejuvenation Dermatology Clinic
Edmonton, Alberta, Canada · Recruiting
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.